{"id":547197,"date":"2026-04-17T22:18:10","date_gmt":"2026-04-17T22:18:10","guid":{"rendered":"https:\/\/www.harrisburgnewsnow.com\/news\/story\/547197\/clinoptima-secures-fully-funded-global-partnership-to-advance-nextgeneration-ripps-therapeutics.html"},"modified":"2026-04-17T22:18:10","modified_gmt":"2026-04-17T22:18:10","slug":"clinoptima-secures-fully-funded-global-partnership-to-advance-nextgeneration-ripps-therapeutics","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/547197\/clinoptima-secures-fully-funded-global-partnership-to-advance-nextgeneration-ripps-therapeutics.html","title":{"rendered":"Clinoptima Secures Fully Funded Global Partnership to Advance Next-Generation RiPPs Therapeutics"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/04\/1776424254.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" class=\"alignnone size-medium wp-image-29\" title=\"Clinoptima Secures Fully Funded Global Partnership to Advance Next-Generation RiPPs Therapeutics\" src=\"https:\/\/www.globalnewslines.com\/uploads\/2026\/04\/1776424254.jpg\" alt=\"Clinoptima Secures Fully Funded Global Partnership to Advance Next-Generation RiPPs Therapeutics\" width=\"225\" height=\"43\" \/><\/a><\/div>\n<div style=\"clear:both\"><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">Clinoptima Bio Research Announces Fully Funded Strategic Partnership With Global Pharmaceutical Leader to Advance Next-Generation RiPPs-Based Therapeutics  <\/div>\n<p style=\"text-align: justify\"><strong>S&atilde;o Paulo, Brazil &#8211;<\/strong>&nbsp;Clinoptima Bio Research (<a rel=\"nofollow noopener\" href=\"https:\/\/clinoptima.io\/\" target=\"_blank\">https:\/\/clinoptima.io\/<\/a>), a leader in AI-enhanced biomedical discovery, today announced a major strategic partnership with Bayer Global (<a rel=\"nofollow noopener\" href=\"https:\/\/www.bayer.com\/en\/\" target=\"_blank\">https:\/\/www.bayer.com\/<\/a>), one of the world&rsquo;s top pharmaceutical innovators, to advance a new generation of Ribosomally Synthesized and Post-Translationally Modified Peptides (RiPPs) for precision therapeutics.<\/p>\n<p style=\"text-align: justify\">Under the agreement, Bayer Global will provide full programme funding, covering research, development, platform integration, laboratory expansion, and all associated pipeline milestones.<\/p>\n<p style=\"text-align: justify\">The collaboration centers on Project FUSION, a multi-year discovery and translational research initiative designed to:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">Generate novel RiPP scaffolds using AI-driven modelling to optimize bioactivity, stability, and selectivity<\/p>\n<\/li>\n<li>\n<p>Engineer post-translational modification pathways including lanthionine formation, heterocycle installation, and macrocyclization<\/p>\n<\/li>\n<li>\n<p>Develop hybrid RiPP&ndash;mRNA strategies, enabling mRNA-encoded expression of engineered RiPP precursors in vivo<\/p>\n<\/li>\n<li>\n<p>Screen preclinical candidates via Clinoptima&rsquo;s predictive simulation environment for binding affinity, mechanism of action, and toxicity<\/p>\n<\/li>\n<li>\n<p>Advance lead RiPP candidates targeting oncology, antimicrobial resistance, and inflammatory disorders<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">The first wave of preclinical candidates is expected in 2027, with IND-enabling studies anticipated from 2028 onward.<\/p>\n<p style=\"text-align: justify\"><strong>Leadership Commentary<\/strong><\/p>\n<p style=\"text-align: justify\">&ldquo;<em>Fully funded partnerships of this scale are rare in early-stage peptide innovation,<\/em>&rdquo; said Dr. Joao Da Silva, CEO of Clinoptima Bio Research. <em>&ldquo;Bayer&rsquo;s commitment not only validates the strength of our AI-driven RiPPs platform but also accelerates our ability to move discoveries into the clinic.<\/em>&rdquo;<\/p>\n<p style=\"text-align: justify\">A senior representative from Bayer noted: &ldquo;<em>Clinoptima&rsquo;s computational and synthetic biology capabilities position them at the forefront of next-generation peptide engineering. Our funding and global infrastructure will allow this partnership to translate promising RiPPs science into meaningful therapeutic breakthroughs.<\/em>&rdquo;<\/p>\n<p style=\"text-align: justify\"><strong>About the Agreement<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Bayer will provide full funding for research, platform development, peptide synthesis, and preclinical advancement.<\/p>\n<\/li>\n<li>\n<p>Joint expenditures support peptide synthesis, mRNA-expression studies, and expansion of Clinoptima&rsquo;s AI cluster.<\/p>\n<\/li>\n<li>\n<p>Clinoptima will lead AI modelling, RiPP design, pathway engineering, and early discovery.<\/p>\n<\/li>\n<li>\n<p>Bayer will manage scale-up, clinical development, regulatory strategy, and commercialization.<\/p>\n<\/li>\n<li>\n<p>Programme milestones include AI platform integration in 2026, candidate selection and IND preparation in 2027.<\/p>\n<\/li>\n<\/ul>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Contact Person:<\/strong> William Smith<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href='http:\/\/www.universalpressrelease.com\/?pr=clinoptima-secures-fully-funded-global-partnership-to-advance-nextgeneration-ripps-therapeutics'>Send Email<\/a><br \/><strong>Address:<\/strong>15 Nutley Rd,   Dublin 4<br \/><strong>City:<\/strong> Dublin D04 V2P8<br \/><strong>Country:<\/strong> Ireland<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/clinoptima.io\/\" target=\"_blank\">https:\/\/clinoptima.io\/<\/a><\/p>\n<p><img loading=\"lazy\" src=\"https:\/\/www.getnews.info\/press_stat.php?pr=clinoptima-secures-fully-funded-global-partnership-to-advance-nextgeneration-ripps-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinoptima Bio Research Announces Fully Funded Strategic Partnership With Global Pharmaceutical Leader to Advance Next-Generation RiPPs-Based Therapeutics S&atilde;o Paulo, Brazil &#8211;&nbsp;Clinoptima Bio Research (https:\/\/clinoptima.io\/), a leader in AI-enhanced biomedical discovery,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/547197"}],"collection":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/comments?post=547197"}],"version-history":[{"count":0,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/547197\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/media?parent=547197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/categories?post=547197"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/tags?post=547197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}